BPC-157
BPC-157 is a lab-made research peptide. Claims about injury and gut benefits rest mostly on animal studies.
Whole vial: 10 mg Vial math ↓
Why people look it up
People often hear about BPC-157 when looking into a stubborn injury or gut problem. Online, it is talked about as a way to help the body repair itself. That interest comes mainly from animal studies; the small human reports so far have not shown that it heals injuries in people.
Tendon and ligament recoveryANIMAL / PRECLINICAL EVIDENCE
A rat Achilles tendon-to-bone study found healing-related changes; this is not a human recovery trial. Read source ↗
Gut protectionANIMAL / PRECLINICAL EVIDENCE
Stomach-injury experiments were done in rats. Read source ↗
Knee-pain reports in peopleLIMITED HUMAN EVIDENCE
A 17-patient chart review included BPC-157 alone and BPC-157 with TB4. Follow-up was mainly a phone survey without a control group or objective evidence of tissue repair. Read source ↗
Bladder-symptom reports in peopleLIMITED HUMAN EVIDENCE
Twelve women described improvement after a single bladder-wall procedure, but the report had no control group and cannot establish benefit or a regimen for another route. Read source ↗
Human injury healingINSUFFICIENT EVIDENCE
Animal findings and online reports do not establish a clinical benefit in people. Read source ↗
The labels show the evidence for each claim. Open a row for its source.
Dosage at a glance
Dosage source summary
- Lower example
- 200 mcg
- Middle example
- 400 mcg
- Higher example
- 600 mcg
- How often
- Once daily in the published example
- Time on / time off
- The chart does not establish an agreed break schedule.
- Route
- Subcutaneous in that chart
Amounts per administration from one published chart, not a community consensus. The survey below describes a different sample.
These source amounts do not establish a safe human dose for a research vial.
Sources & individual reports
- PeptideDosages published chart; reviewed October 18, 2026
Amounts per administration from one published chart, not a community consensus. The survey below describes a different sample. Source check: 2026-10-18.
Source coverage: 1 voluntary survey · 613 self-users · 371 usable numeric answers.
- Amount reported
- 500–1,000 mcg per administration Middle 50% of usable numeric answers; not the full range.
- How often reported
- Daily — 62% of self-users Frequency answers were not matched to the amounts above.
- Reported duration / cycle
- Median 8.7 weeks; middle half 6–16 weeks
- Route (how it was taken)
- Injection — 92% of self-users Route answers were not matched to the amounts above.
How much agreement is there? This describes one self-selected survey. The amount, frequency, duration and route are separate summaries, not one matched protocol or a community-wide consensus.
Read the original survey ↗Survey limitations
Voluntary, self-selected online survey with no verification of compound identity, concentration, or self-reported values. One aggregate source, not independent agreement across multiple communities. It cannot establish an appropriate amount, schedule, route, efficacy, or safety.
Public sources last reviewed: 2026-10-03. Product identity and reported results were not independently verified. Source method →
Evidence, sources & vial math
What the research actually showsHuman studies, evidence limits and mechanisms
What has actually been studied?
Rat studies found changes related to tendon and stomach healing. Two small reports in people looked at knee pain and bladder symptoms, but neither showed that BPC-157 heals injuries in people or established how much to use.
Evidence limits: The small human reports cannot tell us whether BPC-157 caused the improvements people described. We still do not know a proven amount for people, its long-term safety, or whether an online vial matches what researchers studied.
Product status: Research-vial listings are not FDA-approved medicines. Approved-use labels on this page refer only to the named finished prescription product.
Human research
BPC-157 injections for knee pain 2021
What was found: The authors reported pain relief among contacted patients, including 11 of 12 who received BPC-157 alone. This design cannot show what caused the change.
Main limit: Small, uncontrolled, retrospective clinic series; variable knee problems and co-treatment. It does not prove tendon or ligament repair or support use of a research vial.
Study setup and amounts
- Who
- Patients with knee pain at one private clinic; some received BPC-157 plus thymosin beta-4
- Number of participants
- 17 records; 16 contacted at follow-up; 12 of those had BPC-157 alone
- Study design
- Retrospective chart review and phone follow-up, without a control group
- Route
- Intra-articular injection into the knee
- Amount studied
- 2–4 mg BPC-157 in the reported procedures; some patients also received thymosin beta-4
- Frequency
- One procedure for most; two people had a repeat injection after reinjury
- Duration
- Records from 2019–2020; most phone follow-ups 6–12 months after the procedure
- Outcome measured
- Self-reported knee pain; no validated function score or structural healing measurement
BPC-157 bladder-symptom pilot 2024
What was found: The authors reported that participants rated their symptoms improved. Without a control group, the result cannot establish causation.
Main limit: Very small uncontrolled study, specialized procedure, subjective outcome, and no evidence for injury repair or use of a dry research vial.
Study setup and amounts
- Who
- Women with interstitial cystitis who had not responded to pentosan polysulfate
- Number of participants
- 12
- Study design
- Uncontrolled, single-clinic pilot with patient-rated follow-up
- Route
- Injection into the bladder wall during cystoscopy
- Amount studied
- 10 mg total during one procedure
- Frequency
- One procedure
- Duration
- One procedure; follow-up timing is not established from the accessible abstract
- Outcome measured
- Patient-rated Global Response Assessment of bladder symptoms
Study and prescription-product amounts describe those sources. They do not select an amount for an online research vial.
How researchers think it might work
BPC-157 is discussed for tissue and gut effects because animal experiments reported healing-related changes. How it would work in people is not established.
Show scientific explanation
A rat Achilles tendon-to-bone study measured functional and tissue changes after BPC-157 exposure. It cannot establish a human mechanism or regimen. Read supporting source ↗
Vial & syringe mathTurn the vial total and liquid volume into concentration and syringe units
Vial & syringe math
Change the vial total and final liquid volume to see what each U-100 syringe mark represents.
The starting 1 mL is a math example. Enter your final mixed volume to update the numbers.
100 U-100 syringe units = 1 mL. These results assume the labeled amount is evenly mixed through the final liquid volume.
Continue in the calculator →About this listingResearch-use-only status, seller names and additional background
A research material is not intended for human use. Its name or lab report does not establish suitability for a person. What research use only means →
Compiled by PeptideWhy · Scientific sources last checked 2026-10-03 · Editorial policy · Corrections